Unfortunately, there is conflicting evidence showing the efficacy of DPP-4 inhibitors in NASH and NAFLD patients with T2D, although the number of patients involved in these studies is relatively small [33]. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatohepatitis.